



Dynavax Technologies Corporation  
Investor Relations Department  
2929 Seventh Street  
Berkeley, CA 94710  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: DVAX**

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 17.75                      |
| Trade Time:   | 4:00 PM ET<br>Feb 23, 2018 |
| Change:       | 0.40<br>(+2.305%)          |
| Day Range     | 17.20 - 18.10              |
| 52-Week Range | 4.00 - 24.45               |
| Volume        | 1,358,076                  |

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- Feb 21, 2018*  
[Dynavax's HEPLISAV-B™ \[Hepatitis B Vaccine \(Recombinant\), Adjuvanted\] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults](#)
- Feb 20, 2018*  
[Dynavax Secures \\$175 Million in Non-Dilutive Debt Financing](#)
- Feb 14, 2018*  
[Dynavax to Present at the RBC Capital Markets Global Healthcare Conference](#)
- Feb 2, 2018*  
[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Jan 12, 2018*  
[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

### Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 13, 2017*  
[Annual Report \(10-K\)](#)
- Jul 10, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 7, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*  
[Quarterly Report \(10-Q\)](#)